Clinical Trials Logo

Carcinoma, Renal Cell clinical trials

View clinical trials related to Carcinoma, Renal Cell.

Filter by:

NCT ID: NCT00019539 Completed - Clinical trials for Stage IV Renal Cell Cancer

Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer

Start date: November 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them. PURPOSE: Randomized phase II trial to determine the effectiveness of monoclonal antibody therapy in treating patients who have advanced kidney cancer that cannot be surgically removed.

NCT ID: NCT00019396 Completed - Stage IV Melanoma Clinical Trials

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

Start date: February 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: The drug flt3L may stimulate a person's immune system and help to kill tumor cells. Vaccines made from melanoma cells may make the body build an immune response to and kill their tumor cells. PURPOSE: Phase II trial to study the effectiveness of flt3L with or without vaccine therapy in treating patients with metastatic melanoma or renal cell cancer.

NCT ID: NCT00018941 Completed - Kidney Cancer Clinical Trials

Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Start date: April 1991
Phase: Phase 3
Study type: Interventional

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. It is not yet known which regimen of interleukin-2 is most effective for kidney cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of interleukin-2 in treating patients who have metastatic kidney cancer.

NCT ID: NCT00017329 Completed - Kidney Cancer Clinical Trials

PS-341 in Treating Patients With Metastatic Kidney Cancer

Start date: April 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of PS-341 in treating patients who have metastatic kidney cancer.

NCT ID: NCT00016939 Completed - Kidney Cancer Clinical Trials

Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer

Start date: May 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of flavopiridol in treating patients who have unresectable or metastatic kidney cancer.

NCT ID: NCT00014183 Completed - Kidney Cancer Clinical Trials

ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer

Start date: January 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of kidney cancer. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have recurrent or stage IV kidney cancer.

NCT ID: NCT00014131 Terminated - Kidney Cancer Clinical Trials

Vaccine Therapy in Treating Patients With Kidney Cancer

Start date: November 2001
Phase: Phase 1
Study type: Interventional

RATIONALE: Vaccines made from a patient's white blood cells and tumor cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have recurrent or stage III or stage IV kidney cancer.

NCT ID: NCT00012337 Completed - Kidney Cancer Clinical Trials

ZD 1839 in Treating Patients With Metastatic Kidney Cancer

Start date: January 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. Drugs such as ZD 1839 may interfere with the growth factors and cause tumor cells to die. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have metastatic kidney cancer.

NCT ID: NCT00011973 Completed - Kidney Cancer Clinical Trials

Chemotherapy in Treating Patients With Advanced Kidney Cancer

Start date: December 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of fenretinide in treating patients who have advanced kidney cancer.

NCT ID: NCT00009919 Terminated - Clinical trials for Stage IV Renal Cell Cancer

SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment

Start date: December 2000
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of SU5416 in treating patients who have metastatic kidney cancer that has not responded to previous therapy with interleukin-2. SU5416 may stop the growth of kidney cancer by stopping blood flow to the tumor